Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE

https://doi.org/10.20996/1819-6446-2006-2-1-18-24

Full Text:

Abstract

Aim:  to evaluate efficiency and safety of the combined antihypertensive drug Lozap Plus (50 mg losartan, 12,5 mg hydrochlorothiazide) in patients with arterial hypertension (AH) of I-III grade with high and very high cardiovascular risk. Material and methods: 30 patients with AH of I-III grade (13 men and 17 women aged 51.9±1.9) were observed. Patients received Lozan Plus (Zentiva, Czech Republic) 1 time in the morning during 12 weeks. Ambulatory blood pressure monitoring (ABPM), echocardiography, biochemical blood analysis were carried out, microalbuminuria (MA) was determined, quality of life was assessed. Results: After 2 weeks of therapy decrease in office systolic blood pressure (BP) was observed, and after 4 weeks - in diastolic BP. After 12 weeks of treatment decrease in BP became more significant. Target systolic and diastolic BP was reached in 83.3% and 90% of patients respectively. Decrease in systolic BP was observed in 24 hrs. (from 141.9±1.9 to 128.6±0.8 mmHg, p<0.001), in daytime (from 146.8±2.6 to 135.8±1.0 mmHg, p<0.01) and in nighttime (from 131.5±1.9 to 118.8±1.9 mmHg, p<0.001). Diastolic BP also decreased: in 24 hrs. (from 91.7±1.8 to 78.7±1.6 mmHg, p<0.05), in daytime (from 94.3±1.3 to 85.0±1.2 mmHg, p<0.05) and in nighttime (from 83.5±2.0 to 71.2±1.7 mmHg, p<0.01). Daily variability of BP, time index of BP and morning BP rise (from 37.6±2.0 to 23.9±1.9 mmHg, p<0.001) reduced. Normalization of daily profile of BP was observed in the majority of patients after 12 weeks of Lozap Plus therapy. Treatment resulted in reduction of number of patients with myocardial hypertrophy (from 50% to 30%, p<0.01), and of patients with diastolic dysfunction of left ventricle (from 43.3% to 30%, p<0.05). Therapy with Lozap Plus during 12 weeks was followed by decrease in MA from 56.7±1.1 mg/l to 9.0±0.5 mg/l. Lozap Plus demonstrated metabolic safety by assessing carbohydrate, lipid, nitric and electrolyte blood parameters. Increase in quality of life was observed by week 12 of treatment. Conclusion: Lozap Plus is efficient antihypertensive drug providing cardio- and nephroprotection, which doesn’t cause metabolic disturbances and improves quality of life of hypertensive patients.

About the Authors

R. M. Linchak
National Pirogov medico-surgical centre of Roszdrav
Russian Federation


K. M. Shumilova
National Pirogov medico-surgical centre of Roszdrav
Russian Federation


A. D. Martinyuk
National Pirogov medico-surgical centre of Roszdrav
Russian Federation


T. A. Gusaim
National Pirogov medico-surgical centre of Roszdrav
Russian Federation


E. V. Semyonova
National Pirogov medico-surgical centre of Roszdrav
Russian Federation


L. G. Zhirova
National Pirogov medico-surgical centre of Roszdrav
Russian Federation


S. A. Boitsov
National Pirogov medico-surgical centre of Roszdrav
Russian Federation


References

1. Литвин А.Ю. Гипертоническая болезнь и микроальбуминурия. Кардиология 1996; 6, 9: 74-81.

2. Ощепкова Е.В., Рогоза А.Р., Варакин Ю.А. Вариабельность артериального давления (по данным суточного мониторирования) при мягкой артериальной гипертонии. Тер. архив 1994; 8: 70-73.

3. Рунихина Н.К., Рогоза А.Н., Вихерт О.А. Суточный профиль артериального давления и структурно-функциональные изменения сердечно-сосудистой системы при начальной стадии гипертонической болезни. Тер. Архив 1997; 4: 39-42.

4. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации. Комитет ВНОК. Секция артериальной гипертонии. М, 2001.

5. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации. Комитет ВНОК. Секция артериальной гипертонии. М, 2004.

6. Chobanian A. V., Bakris G.L., Black H.R. et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-72.

7. Devereux R.B., Pickering T.G., Harshfield G.A. et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regulary reccur-ing stress. Circulation 1998; 68: 447-76.

8. Guidelines Sub–Commitee. 1999 World Health Organization – International Society of hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.

9. Ljungman S., Wikstrand J., Hartford M. Et al. Urinary albumin excretion a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am. J. Hypertens. 1996; 9, 8: 770-8.

10. Meredith P.A., Perloff D., Mancia G. et al. Blood pressure variability and its implica-tions for antihypertensive therapy. Blood Press. 1995; 4: 5-11.

11. Palatini P., Pessina A.C., Graniero G.R. et al. The relationship between overweight, life style and casual and 24-hour pressures in a population of male subjects with mild hypertension. The results of the harvest study. G. Ital. Cardiol. 1995; 25, 8: 977-89.

12. Staessen J., Fagard R., Lijnen P. Reference values for ambulatory blood pressure: a metaanalysis. Ibit. 1990; 8, 6: 67-9.

13. 2003 European Society of hypertension – European Society of cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21: 1011 – 53.


For citation:


Linchak R.M., Shumilova K.M., Martinyuk A.D., Gusaim T.A., Semyonova E.V., Zhirova L.G., Boitsov S.A. ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE. Rational Pharmacotherapy in Cardiology. 2006;2(1):18-24. (In Russ.) https://doi.org/10.20996/1819-6446-2006-2-1-18-24

Views: 461


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)